Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients. A Selection of Papers from the Third Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)

Dear Colleagues,

Since 2018, FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (MDACC) (Houston, Tx, USA) hosting annual meetings dedicated to recent advances in lung cancer. These meetings were held in person in Nice and then in Houston. This year, on October 4th, the third Joint Meeting on Lung Cancer (JMLC) will be virtually due to COVID-19.  This meeting will be co-organized by George Calin, Sendurai Mani and Ignacio Wistuba from the MDACC and by Paul Hofman from the FHU OncoAge.  At this third JMLC meeting, experts from the MDACC and for the FHU Oncoage will present the last advances in different fields of thoracic oncology, including new therapeutic options (in targeted therapy and immunotherapy fields), new predictive biomarkers, as well as new discoveries in lung carcinogenesis.

The main objective of the Special Issue is to summarize the current trends and discuss different topics linked to lung cancer based on the presentations from the third JMLC meeting. Importantly, this Special Issue will promote understanding of new therapeutic options for lung cancer patients in the near future and decipher the mechanisms of lung carcinoma development and progression.

Prof. Dr. Paul Hofman
Prof. Dr. George A Calin
Dr. Ignacio I. Wistuba
Dr. Sendurai A. Mani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.